MedPath

National Registry of Cardioneuroablation in Recurrent Reflex Syncope

Recruiting
Conditions
Syncope, Vasovagal
Heart Arrest
Bradycardia
Registration Number
NCT06159764
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

This registry aims to collect patient data on cardioneuroablation for vasovagal syncope from multiple centers in France. The aim is to evaluate success rates, compare techniques and help institutions set up their own cardioneuroablation program

Detailed Description

Cardioneuroablation is an emerging technique used to treat patients with vagally-mediated extrinsic bradycardia. It seems particularly efficient in patients with recurrent vasovagal syncope due to a strong cardioinhibitory effect. The procedure consists in using radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias. Key questions concerning this procedure still remain unanswered: 1) What is the success rate of the procedure 2) Which patients will benefit from this technique? 3) Which fat pads should be targeted during the procedure? 4) What is the best way of identifying the location of these fat pads? 5) What are the long-term effects of this procedure? A multicenter registry seems ideal to try to answer these questions at minimal cost

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients aged 18 or more
  • Recurrent vasovagal syncope (≥2 episodes during the last year) with an asystolic component (≥3 second pause) recorded during a spontaneous episode. The asystole can be related to sinus arrest or paroxysmal AV block.
  • Scheduled cardioneuroablation procedure
  • Estimated residual battery life ≥ 1 year.
  • Patient affiliated to or beneficiary of national health security scheme.
  • Patient who have received an information notice and has not objected to the use of their data in the registry.
Exclusion Criteria
  • Contraindication to anticoagulation therapy: major bleeding, risk of major bleeding, severe hepatic disease
  • Contraindication to cardiac CT: contrast medium allergies
  • Intracardiac thrombus
  • Patient detained by judicial or administrative decision.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence of vasovagal syncope12 months

Number of patients with recurrence

Secondary Outcome Measures
NameTimeMethod
Assessment of technical learning curve by centre12 months

procedure time

Recurrence of vasovagal syncope in different subgroups12 months

Number of patients with recurrence

Efficacy of cardioneuroablation procedure12 months

Number of asystolic pauses

prevalence of post-ablation pre-syncopal events12 months

Number of post-ablation pre-syncopal events

correlation between ablation sites and epicardial fat pads12 months

spatial correlation between ablation sites and epicardial fat pads

Quality of life of post-ablated patients (Score 1)12 months

ISQoL score (Impact of syncope on quality of life) (0-55, lower scores indicate less impact of syncope on HRQoL \[better\]

Quality of life of post-ablated patients (Score 2)12 months

SFSQ score (Syncope Functional Status HR-QoL Questionnaire) (0-100, lower scores indicate less impact of syncope \[better\])

Trial Locations

Locations (14)

CHU de Montpellier

🇫🇷

Montpellier, France

Institut ARNAULT TZANCK

🇫🇷

Saint-Laurent-du-Var, France

Hôpital Louis Pradel

🇫🇷

Bron, France

CHU Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

CHU Lille

🇫🇷

Lille, France

Hôpital de la Timone

🇫🇷

Marseille, France

Clinique du Millénaire

🇫🇷

Montpellier, France

Hôpital Pitié-Salpêtriére

🇫🇷

Paris, France

Hôpital européen Georges Pompidou

🇫🇷

Paris, France

Hôpital Haut-Lévèque

🇫🇷

Pessac, France

Scroll for more (4 remaining)
CHU de Montpellier
🇫🇷Montpellier, France
Mathieu GRANIER
Contact
m-granier@chu-montpellier.fr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.